Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)

Denise A. Yardley; Adam Brufsky; Robert E. Coleman; Pierfranco F. Conte; Javier Cortes; Stefan Glueck; Jean-Mark A. Nabholtz; Joyce O'Shaughnessy; Robert M. Beck; Amy Ko; Markus F. Renschler; Debora Barton; Nadia Harbeck

doi:10.1186/s13063-016-1195-6

Back

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)

Journal article

Open access

Peer reviewed

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)

Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Pierfranco F. Conte, Javier Cortes, Stefan Glueck, Jean-Mark A. Nabholtz, Joyce O'Shaughnessy, Robert M. Beck, Amy Ko, …

Trials, Vol.17

03/02/2016

DOI: https://doi.org/10.1186/s13063-016-1195-6

PMID: 26841937

Abstract

Life Sciences & Biomedicine

Medicine, Research & Experimental

Research & Experimental Medicine

Science & Technology

Files and links (1)

url

https://doi.org/10.1186/s13063-016-1195-6View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)
Creators - without role: Denise A. Yardley - Tennessee Oncology
Adam Brufsky - University of Pittsburgh Medical Center
Robert E. Coleman - Weston Park Cancer Centre
Pierfranco F. Conte - Istituto Oncologico Veneto
Javier Cortes - Vall dHebron Inst Oncol VHIO, Barcelona, Spain
Stefan Glueck - Celgene Corp, Summit, NJ USA
Jean-Mark A. Nabholtz - Ctr Lutte Canc Auvergne, Clermont Ferrand, France
Joyce O'Shaughnessy - Texas Oncology
Robert M. Beck - Celgene Corp, Summit, NJ USA
Amy Ko - Celgene Corp, Summit, NJ USA
Markus F. Renschler - Celgene Corp, Summit, NJ USA
Debora Barton - Celgene Corp, Summit, NJ USA
Nadia Harbeck - Univ Munich, Breast Ctr, Munich, Germany
Publication Details: Trials, Vol.17
Publisher: Springer Nature
Number of pages: 1
Identifiers: 9948553308331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article